Edition:
India

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

31.07USD
23 Feb 2018
Change (% chg)

$1.24 (+4.16%)
Prev Close
$29.83
Open
$29.97
Day's High
$31.42
Day's Low
$29.32
Volume
488,882
Avg. Vol
448,657
52-wk High
$55.94
52-wk Low
$24.45

Select another date:

Wed, Feb 21 2018

BRIEF-The Medicines Q4 GAAP Loss Per Share $2.19 From Continuing Operations

* THE MEDICINES COMPANY REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 BUSINESS AND FINANCIAL RESULTS

BRIEF-The Medicines Company Reaches Enrollment Target For Orion-9 Ahead Of Schedule

* THE MEDICINES COMPANY REACHES ENROLLMENT TARGET FOR ORION-9 AHEAD OF SCHEDULE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Medicines Co Reports 10.6 Pct Passive Stake In Melinta Therapeutics

* THE MEDICINES COMPANY REPORTS 10.6 PERCENT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN. 5, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2muRQBT) Further company coverage:

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

BRIEF-Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company

* MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY Source text for Eikon: Further company coverage:

BRIEF-Medicines Co names Fred Eshelman executive chairman

* The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors

BRIEF-SymBio Pharmaceuticals says arbitration against The Medicines Company

* Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for the exclusive rights to develop and commercialize the patient-controlled pain management drug "SyB P-1501" (or "IONSYS") in Japan

BRIEF-The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran

* The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran

BRIEF-The Medicines Company reports third-quarter 2017 business and financial results

* The Medicines Company reports third-quarter 2017 business and financial results

BRIEF-The Medicines Company announces FDA approval of Vabomere

* The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam)

Select another date: